MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Hutchmed begins registration stage for sovleplenib phase 2/3 trial

ALN

Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Shares in Hutchmed were down 7.6% to 254.50 pence each in London on Friday morning.

wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options, Hutchmed said.

The Hong Kong-based developer of treatments for cancer and immunological diseases said this follows positive data from the proof-of-concept phase 2 stage of the trial and subsequent consultation with the China National Medical Products Administration.

If positive, Hutchmed said the data from the trial may be used to support a future new drug application filing.

The first phase 3 patient received their initial dose on Wednesday. Hutchmed said 21 patients have been enrolled in the study so far and approximately 90 more patients are expected to be enrolled to this registration stage.

Copyright 2024 Alliance News Ltd. All Rights Reserved.